Spruce Completes Pre-BLA Meetings with FDA for MPS IIIB Therapy

Spruce Biosciences has successfully concluded its pre-Biologics License Application (BLA) meetings with the U.S. Food and Drug Administration (FDA) for its MPS IIIB therapy.